ClinicalTrials.gg
RecruitingNCT07198633Updated Jun 2, 2026

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

A Phase 1/2 interventional study of QLC5508 and abiraterone acetate in Advanced Prostate Cancer, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
212
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 541 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 51 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
135th of 435
212 · median 100
Started
2025
with 77 others
Phase 1/2
52 of 541
30 open now
Primary completion
2026-12
later than 142 of 341 live
Registered
431st of 541
by date

Among the 541 studies in Prostatic Neoplasms with a site in China, this one is the 135th largest by planned enrollment of the 435 interventional ones that give a count, is one of 78 that started in 2025, is one of 52 in phase 1/2, reaches primary completion later than 142 of the 341 other live ones, and was the 431st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 541 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

276 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 541 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, multicenter Phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of QLC5508 in combination with NHA (abiraterone or enzalutamide), QLC5508 in combination with QLH12016, QLC5508 in combination with QLH12016 and NHA (abiraterone or enzalutamide), and QLH12016 in combination with NHA (abiraterone or enzalutamide) in subjects with advanced prostate cancer.

The study consists of two stages:

Phase Ib: is the combination dose-escalation stage, during which the recommended Phase II dose (RP2D) will be determined.

Phase II is the efficacy exploration stage, in which, based on the RP2D established in Phase Ib, the therapeutic efficacy will be further evaluated in the target indication.

03

Conditions studied

  • Advanced Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject voluntarily agrees to participate and has signed the form.
  • Male, aged ≥18 years.
  • (ECOG) performance status score of 0-1.
  • of at least 3 months.
  • or cytologically confirmed adenocarcinoma of the prostate.
  • Radiologically confirmed prostate cancer.
  • For subjects with mCRPC, serum testosterone must be at castrate levels, and they must have demonstrated either PSA progression or radiographic progression.
  • Must have undergone surgical castration or be willing to receive medical castration.
  • For Phase Ib, subjects must have experienced failure, intolerance, or refusal of standard therapy.
  • Adequate function of major organs as defined by the protocol.
  • Agreement to use effective during the study (except for subjects who have undergone bilateral orchiectomy).
  • Sufficient blood samples must be provided during the screening period for genetic mutation testing.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with the following agents: AR PROTAC, abiraterone, enzalutamide, or B7H3-targeted therapies.
  • Presence of central nervous system (CNS) , , or spinal cord compression requiring hormonal therapy.
  • Receipt of extensive radiotherapy within 4 weeks prior to the first administration of the medicinal product.
  • Treatment with other investigational drugs or major surgery within 4 weeks prior to the first administration of the investigational medicinal product.
  • Presence of factors that may affect drug administration, intake, or absorption.
  • History of epilepsy, or a condition that could provoke seizures within 12 months prior to the first administration of the investigational medicinal product.
  • Known history of substance abuse, alcoholism, or drug addiction; or prior history of significant neurological or psychiatric disorders, including dementia or hepatic encephalopathy.
  • Presence of severe cardiovascular or cerebrovascular disease.
  • Active, uncontrolled infection.
  • Clinically uncontrolled third-space fluid accumulation prior to the first administration of the investigational medicinal product.
  • History of other within 5 years prior to the first administration of the investigational medicinal product.
  • Presence of moderate to severe pulmonary disease that significantly impairs lung function.
  • For subjects receiving QLC5508, history of non-infectious interstitial lung disease (ILD) or pneumonitis.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    QLC5508+NHA

    Drug: QLC5508 · Drug: abiraterone acetate · Drug: enzalutamide

  • Experimental
    QLC5508+QLH12016

    Drug: QLC5508 · Drug: QLH12016

  • Experimental
    QLC5508+QLH12016+NHA

    Drug: QLC5508 · Drug: abiraterone acetate · Drug: enzalutamide · Drug: QLH12016

  • Experimental
    QLH12016+NHA

    Drug: QLC5508 · Drug: abiraterone acetate · Drug: enzalutamide

Interventions

  • B7H3 ADC; QLC5508 will be administered by injection at the dose and dosing frequency specified in the protocol.

  • An oral CYP17 inhibitor; abiraterone acetate will be administered orally at the dose and dosing frequency specified in the protocol

  • An oral androgen receptor inhibitor; enzalutamide will be administered orally at the dose and dosing frequency specified in the protocol.

  • An oral androgen receptor PROTAC; QLH12016 will be administered orally at the dose and dosing frequency specified in the protocol

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) (Phase Ib)

    MTD is defined as the previous dose level at which 2 or more out of 2-6 subjects experienced a DLT

    Time frame: At the end of Day 28 after the first dose

  2. Maximum administered dose (MAD)(Phase Ib)

    MAD is defined as follows: a) based on PK data, it is anticipated that at this dose level, the dose-exposure plateau has been reached, b) based on existing safety data, it is judged that dose escalation following this dose level will have a large safety risk or subject intolerance, or c) based on the PK-PD model, it suggested that the optimal target concentration of safety and efficacy has been explored.

    Time frame: At the end of Day 28 after the first dose

  3. recommended phase II dose (RP2D) (Phase Ib)

    The RP2D will be comprehensively evaluated based on the safety, PK characteristics, and efficacy data from the Phase Ib study.

    Time frame: Through phase Ib completion, an average of 1 year.

  4. The incidence and severity of adverse events (AE) (Phase Ib)

    Incidence and severity of adverse events (AEs) evaluated according to the NCI-CTCAE v5.0

    Time frame: Through phase Ib completion, an average of 1 year.

  5. PSA50 response(Phase II)

    Proportion of subjects with ≥ 50% PSA decrease

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

  6. Objective response rate (ORR) (phase II)

    Best response until progression, as defined by RECIST 1.1 and PCGW3.

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 97 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 13 months is below that.

Counting every sponsor, half of 211 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Sep 30, 2025
StartActual
Nov 5, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07198633
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Nov 5, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 2, 2026

Study contacts

Xin Yao, PHD
Contact
yaoxin@tjmuch.com
18622221103

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLH12016

Start the discussion